Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes

Andrew O. Odegaard1*, David R. Jacobs Jr.2, Otto A. Sanchez2, David C. Goff Jr.3, Alexander P. Reiner4 and Myron D. Gross2,5

Abstract
Background: Oxidative stress, inflammation and endothelial dysfunction are interrelated factors in the etiology of cardiovascular disease, but their linkage to type 2 diabetes is less clear. We examined the association of these biomarkers with incident type 2 diabetes (T2D).

Methods: Analysis of 2339 participants in the community-based coronary artery risk development in young adults (CARDIA) study. Participants (age 40.1 ± 3.6 years, 44% Black, 58% women) were free of diabetes, and were followed 10 years. Cox regression was used to estimate hazard ratios (HRs) for incident T2D adjusting for the other biomarkers under study, demographic and lifestyle measures, dietary biomarkers, BMI (kg/m²) and metabolic syndrome components.

Results: F2-isoprostanes and oxidized LDL (oxidative stress) were positively associated with incident T2D, but the associations were attenuated by adjustment for BMI. C-reactive protein was positively associated with T2D even with full adjustment: HR (95% CI) = 2.21 (1.26–3.88) for quartile 4 (Q4) v. quartile 1 (Q1). The HR (95% CI) for T2D for biomarkers of endothelial dysfunction ICAM-1 and E-selectin for Q4 v. Q1 were 1.64 (0.96–2.81) and 1.68 (1.04–2.71) respectively, with full adjustment. Including these two markers in a common risk score incorporating BMI and clinical measures improved the prediction probability of T2D: relative risk for the average person classified up compared to the average person classified down: 1.09, (1.06–1.13), P < 0.0001.

Conclusions: Biomarkers of inflammation and endothelial dysfunction were positively associated with incident T2D. ICAM-1 and E-selectin add to the prediction of T2D beyond a common risk score.

Keywords: Young adults, oxidative stress, Inflammation, Endothelial dysfunction, Incidence, Type 2 diabetes

Background
Oxidative stress, inflammation, and endothelial dysfunction are interrelated components of an etiological network that has been linked to the development of cardiovascular disease (CVD) [1]. This relationship with CVD is exacerbated in those with perturbations in glucose homeostasis such as insulin resistance and diabetes [2, 3]. Oxidative stress, inflammation, and endothelial dysfunction may be ameliorated by a healthy diet and lifestyle and have also been linked to the etiology of insulin resistance and type 2 diabetes (T2D), and thus hypothesized as unifying components tying vascular factors to metabolic and cardiovascular risk [4, 5].

The oxidative stress aspect of this hypothesis is largely born out of evidence from animal and in vitro studies demonstrating that chronic levels of oxidative stress are among the earliest abnormalities in the natural history of insulin resistance and T2D [6]. However, the evidence is less developed in human and population based studies [7–10]. On the other hand the evidence for inflammation in the etiology of T2D is broad. A recent meta-analysis...
showed a dose–response association between higher levels of inflammatory markers and incidence of T2D [11], although the true mechanism is not well understood and related evidence suggests that elevated levels of inflammation may be intermediates in the pathophysiology of T2D [12]. Related to these concepts, we have previously reported that markers of oxidative stress and inflammation predict the development of insulin resistance and the metabolic syndrome [7, 8, 13]. Lastly, endothelial dysfunction may be a cause or a consequence of oxidative stress and inflammation and is hypothesized to be essential to both the development of T2D and CVD [4]. Indeed, a handful of studies have reported that elevated markers of endothelial dysfunction are associated with increased risk of T2D [14–18].

We are able to study this etiological network of biomarkers in relation to the incidence of T2D in a different context than previous reports. Therefore, we examined the associations of oxidative stress (F2-isoprostanes and oxidized LDL), inflammation (C-reactive protein), and endothelial dysfunction (cellular adhesion molecules) with incidence of T2D. We hypothesized that these biomarkers would positively associate with T2D and add to prediction of incident T2D beyond a common clinical risk score.

**Methods**

**Study and data collection**

CARDIA is a multicenter, longitudinal investigation of the evolution of cardiovascular disease risk starting in young adulthood [19]. The study began in 1985–1986 with 5115 black and white adults aged 18–30 years from four metropolitan areas (Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA). Study participants were sampled to obtain roughly equal numbers of blacks (51.5 %) and whites (48.5 %), men (45.5 %) and women (54.5 %), ages 18–24 years (44.9 %) and 25–30 years (55.1 %), and with a high school education or less (39.7 %) vs more than a high school education (60.3 %). Participants were contacted by telephone every year and examined in person at baseline and 2, 5, 7, 10, 15, 20, and 25 years after baseline. The CARDIA study was approved in person at baseline and 2, 5, 7, 10, 15, 20, and 25 years after baseline. The CARDIA study was approved in the University of Minnesota. Specifically, serum oxidized LDL concentrations were measured by competitive ELISA (Mercodia, Uppsala, Sweden) [8]. Plasma F2-isoprostanes were measured with gas chromatography-mass spectrometry [23]. Serum carotenoid and tocopherols were measured as part of the Young Adult Longitudinal Trends in Antioxidants (YALTA), an ancillary study to CARDIA in the Molecular Epimediology and Biomarker Research Laboratory (MEBRL) in the University of Minnesota. Specifically, serum oxidized LDL concentrations were measured by competitive ELISA (Mercodia, Uppsala, Sweden) [8]. Plasma F2-isoprostanes were measured with gas chromatography-mass spectrometry [23]. Serum carotenoid and tocopherol measurements were based on high performance liquid chromatography [24]. High-sensitivity ELISA was used to measure serum C-reactive protein (CRP) [13]. Cellulosic adhesion molecules (CAMs) were measured at the MEBRL. E-selectin (serum) and P-selectin (plasma) levels were measured with ELISA methods from R and D systems Inc (Cat No: DSLE00 and BBE6, respectively.) Soluble intercellular adhesion molecule-1 (ICAM-1) (serum) and vascular cellular adhesion molecule-1 (VCAM-1) (plasma) concentrations were measured by ELISA methods (R and D systems: DY720 for ICAM-1 and DVC00 for VCAM [25]. This assay was not affected by ICAM-1 single nucleotide polymorphism (SNP) rs5491, which occurs primarily in blacks and blocks ICAM-1 detection by some antibodies.

**Assessment of diabetes**

Type 2 diabetes was defined as use of diabetes medication (assessed at every visit), a fasting blood glucose level of ≥7 mmol/l (126 mg/dl) (measured at years 15–25), 2 h post-challenge glucose ≥11.1 mmol/l (200 mg/dl) (performed at the year 20, 25 exams), or a HbA1c ≥6.5 %
(48 mmol/mol) (assessed at the year 20 and 25 visits). Participants were free of diabetes at year 15 according to medication and fasting glucose criteria examined at all examinations up to and including year 15.

**Statistical analysis**

This analysis was restricted to participants in the year 15 exam, the first exam at which all biomarkers of interest were measured in blood collected in a single sitting. We included all participants without a history of diabetes or an adjudicated cardiovascular disease event prior to year 15 [26], who also participated in at least one of the year 20 or 25 exams and had complete data on the spectrum of oxidative stress, inflammation, and endothelial dysfunction biomarkers as well as the covariates included in the analyses. Final sample size was 2339. Of note, only 1982 participants had a measure of VCAM. However, sensitivity analyses for the other biomarkers limiting the overall analytic population to N = 1982 did not display different results, and VCAM had no significant statistical effect in any of the models, thus to improve precision of estimates our analytic sample was N = 2339.

For each biomarker subjects were classified into quartiles based on their levels and participant characteristics were calculated by these quartiles. Proportional hazards (Cox) regression (SAS Proc PHREG) was used to examine the association between the quartiles of each of the biomarkers and incident T2D. We estimated the hazard ratio (HR) and corresponding 95% confidence interval (CI). Time to event was calculated from the baseline examination (year 15) as 5 or 10 years, namely the timing of the first follow-up examination meeting the criteria for the incident outcome (cases) or censoring at the last CARDIA exam without the incident outcome (censored).

A sequential modeling approach was applied. At later steps of the modeling, covariates were included that may or may not be on hypothetical causal pathways or may be co-determinants of risk. The main model included age (years), study center, race, sex, education (years), cigarette smoking (current, former, never), physical activity (units/week), alcohol consumption (ml/day), family history of diabetes and sum of serum α and γ tocopherols. We have reported that Sum4Carot is related to oxidative stress, endothelial dysfunction and inflammatory biomarkers [27], BMI [28], hypertension [29], and diabetes and smoking [24]. Serum carotenoids largely reflect dietary intake of fruit and vegetables [30].

Model 2 included model 1 plus the measures of oxidative stress, inflammation and endothelial dysfunction not included in model 1. Model 3 added BMI to model 2. The last model included a metabolic syndrome (MetS) cluster score, consisting of the average of standardized deviates of the primary components of the MetS (i.e., the average of the z scores of waist circumference, systolic blood pressure, triglycerides, inverse HDL-cholesterol, and fasting glucose) [31]. The score at any age can be computed as: 1/5*((waist circumference − 77.7)/11.4 − (HDL-cholesterol − 44.6)/10.2 + (triglycerides − 90.5)/52.9 + (SBP − 107.6)/9.2 + (glucose − 88.2)/7.4) [31]. A higher z-score indicates that the components tend to cluster in the higher sections of the distributions, i.e., represent overall higher risk. High scores are almost always the result of high values in two or more components. Consideration of coronary artery calcified plaque (CAC) as a measure of subclinical cardiovascular disease was considered in a sensitivity analysis. Details on the assessment of CAC are reported elsewhere [25]. Presence of CAC was defined as a non-zero Agatston score.

Additionally, we created an endothelial dysfunction index to test for any additive association of the different endothelial dysfunction biomarkers as well as test for an extended dose–response relationship. The hypothesis for this approach was informed by research showing the CAMs work in a “cascade” fashion in atherosclerosis [32], and thus higher levels of multiple CAMs reflect greater endothelial activation/inflammation (dysfunction) than an individual CAM. In an intermediary approach we summed the quartile ranks of the positively associated endothelial dysfunction biomarkers in this analysis with a similar modeling approach. There was no evidence that proportional hazards assumptions were violated for any of the exposures as indicated by the lack of significant interaction between them and time in the models. Tests for trend were performed entering the continuous variable of each biomarker into the models. Effect modification of the associations was considered by BMI, race, and sex.

Lastly, we examined whether these different biomarkers improved the prediction of diabetes relative to a common risk score utilized in research and clinical settings [33]. Due to concerns with net reclassification index (NRI) [34–37], we devised an alternative method. Specifically, to assess the improvement in prediction probability of an alternative risk score (formed by adding variables to a base risk score), we examined the gradient of observed diabetes risk across the reclassification of the predicted probability of the common base risk score. We formed a base risk score as the estimated mean, μB, of a Poisson distribution for predicting incident diabetes that included age, sex, race, family history, body-mass index, fasting glucose level, systolic blood pressure, high-density lipoprotein cholesterol level, and triglyceride level. Each person’s predicted base risk was saved and converted to a base probability using the formula $1 - e^{-μB}$. We then
formed alternative risk scores by adding variables to the base risk score that were positively associated with incident T2D independent of the base risk score covariates in our Cox regression models, updating μB to μA, and forming the alternative probability $1 - e^{-μA}$. For each participant, we subtracted alternative probability—base probability to get the reclassification probability (alternative probability $≥$ base probability corresponds to reclassification up, alternative probability $<$ base probability corresponds to reclassification down).

The measure of improvement in prediction probability has two parts: a graphic and a regression coefficient. The graphic displays the observed incident diabetes risk across reclassification probability (downward reclassification and upward reclassification) within quartiles of the base probability. An upward trend within a base risk category from downward reclassification probability—upward reclassification probability indicates improved prediction probability. The regression coefficient arises in a further Poisson regression of incident diabetes (dependent variable) on reclassification probability, adjusting for base probability. The regression coefficient provides the estimated risk difference between the average person who is reclassified up (75th percentile of the reclassification probability) vs the average person who is reclassified down (25th percentile of the reclassification probability distribution) and is expressed as relative risk.

A statistically significant regression coefficient indicates the existence of improved prediction probability and the magnitude of the relative risk indicates the extent of improvement in prediction probability. All analyses were conducted with SAS statistical software version 9.2 (SAS Institute, Cary, NC).

**Results**

The study sample of 2339 participants was aged 32–47 years old (±3.6), was 56% white, and 58% women. Incident diabetes occurred in 222 people (9.5%). Table 1 displays descriptive measures at year 15 for each of the main variables of interest.

Table 2 displays the hazard ratios for incident T2D according to levels of oxidative stress and inflammation. Relative to the lowest levels (bottom quartile) of F2-isoprostanes a monotonic positive association for risk of T2D in quartiles 2–4 was observed after adjustment for demographic, lifestyle, serum carotenoids and tocopherols, and the other markers of oxidative stress, inflammation, and endothelial dysfunction. Upon adjustment for BMI the association was attenuated. The other marker of oxidative stress in the cohort, oxidized LDL, displayed a threshold association where relative to quartile 1, quartile 3 and 4 displayed a similar magnitude of positive association with incident T2D after adjustment for demographic, lifestyle, and other components of the etiological network. The association was largely attenuated upon adjustment for BMI and the continuous metabolic syndrome cluster score, although it persisted for Q3 v. Q1. There was a strong positive association between higher levels of inflammation (CRP) and incident T2D. The nature of the association was graded in quartiles 2–4 after adjustment for demographics, lifestyle factors and serum carotenoids and tocopherols; although the associations in Q2 and Q3 were positive but varying in strength and the estimates of HR became non-significant with adjustment for the other components of the etiological network. The magnitude of the association was strong for Q4 v. Q1 even after full adjustment for BMI and the MetS cluster score.

Table 3 displays the hazard ratios for T2D according to levels of cellular adhesion molecules (CAMs), markers of endothelial dysfunction. There was a strong, graded positive association in Q2–Q4 of ICAM-1 relative to Q1 for incident T2D after adjustment for demographic, lifestyle, etiologic network covariates, and BMI. However, adjustment for the MetS cluster score attenuated the significance of the association. The strong, graded positive association between levels of E-selectin and T2D was significant even after full adjustment. On the other hand there was no association between P-selectin and VCAM with incident T2DM.

To test the hypothesis that higher levels of multiple CAMs reflect greater endothelial dysfunction and portend higher risk for T2D than an individual CAM we created an endothelial dysfunction index adding the quartiles of E-selectin and ICAM-1 with a possible rank sum of 2–8, the sum of two representing being in both the lowest quartile of each CAM and eight representing being in the highest quartile of each. The results of this analysis are presented in Table 4. Relative to a rank sum of 2–3, there was no association in scores of 4–5, but a strong, graded positive association for an index score range of 6–8. Including all four CAMs in the index did not change the magnitude of the estimates, but provided less precision (data not presented).

Figure 1 presents the results of the Improvement in Prediction Probability analysis. The graphic displays the results for the addition of E-selectin and ICAM-1 as continuous variables to the base risk score. Within the graphic the observed diabetes incidence was plotted as a reference across quartiles of the base risk score along with downward and upward reclassification probability according to the alternative risk score. The upward trends across categories indicate an improvement in prediction probability over the base probability for that base risk quartile. The formal statistical tests and regression coefficient confirm this as the Relative
Table 1  Participant characteristics according to levels of oxidative stress, inflammation, and endothelial dysfunction: CARDIA Year 15 (2000–2001)

|                          | Q1   | Q2   | Q3   | Q4   |
|--------------------------|------|------|------|------|
| **Oxidative stress**    |      |      |      |      |
| F2-Isoprostanes          |      |      |      |      |
| N                        | 591  | 576  | 579  | 593  |
| F2-Isoprostanes (ng/mL)  | 31.9 (5.0) | 44.5 (3.4) | 58.2 (34.4) | 100.2 (36.3) |
| Age (years)              | 40.3 (3.6) | 39.9 (3.5) | 40.3 (3.7) | 40.0 (3.8) |
| Race (% black)           | 41.0 | 46.0 | 42.0 | 47.0 |
| Sex (% female)           | 46.0 | 49.0 | 57.0 | 82.0 |
| Education (years)        | 15.4 (2.5) | 15.0 (2.5) | 15.2 (2.5) | 14.9 (2.3) |
| BMI (kg/m²)              | 26.2 (4.6) | 26.9 (4.9) | 28.2 (6.1) | 31.7 (7.6) |
| Smoking (% current)      | 13.4 | 19.1 | 20.4 | 22.4 |
| Alcohol (% light-moderate) | 45.8 | 47.4 | 41.1 | 30.8 |
| Alcohol (% heavy)        | 7.8  | 10.9 | 14.2 | 14.3 |
| Physical activityc       | 393.2 (281.4) | 384.7 (286.2) | 336.2 (266.3) | 276.1 (239.9) |
| Carotenoid index         | 81.9 (46.4) | 70.6 (36.5) | 61.4 (28.8) | 51.2 (26.7) |
| **Oxidized LDL**         |      |      |      |      |
| N                        | 580  | 588  | 598  | 573  |
| Oxidized LDL (U/L)       | 48.4 (9.3) | 69.7 (4.8) | 86.2 (5.5) | 113.9 (14.7) |
| Age (years)              | 40.1 (3.7) | 40.2 (3.6) | 40.0 (3.5) | 40.1 (3.8) |
| Race (% black)           | 38.0 | 45.0 | 45.0 | 48.0 |
| Sex (% female)           | 69.0 | 63.0 | 53.0 | 47.0 |
| Education (years)        | 15.4 (2.5) | 15.2 (2.5) | 15.1 (2.5) | 14.8 (2.4) |
| BMI (kg/m²)              | 26.0 (5.7) | 28.1 (6.6) | 28.6 (5.9) | 30.3 (6.2) |
| Smoking (% current)      | 17.5 | 18.3 | 20.0 | 19.3 |
| Alcohol (% light-moderate) | 39.1 | 40.9 | 43.6 | 41.4 |
| Alcohol (% heavy)        | 14.5 | 11.6 | 10.8 | 10.2 |
| Physical activity        | 366.8 (270.5) | 348.9 (281.2) | 346.3 (274.4) | 328.6 (264.0) |
| Carotenoid index         | 67.9 (40.2) | 67.8 (38.8) | 65.4 (35.0) | 64.0 (34.6) |
| **Inflammation**         |      |      |      |      |
| C-reactive protein       |      |      |      |      |
| N                        | 582  | 602  | 587  | 568  |
| C-reactive protein (mg/L)| 0.31 (0.12) | 0.84 (0.22) | 2.23 (0.63) | 8.82 (7.24) |
| Age (years)              | 39.9 (3.4) | 40.2 (3.6) | 40.4 (3.7) | 39.9 (3.82) |
| Race (% black)           | 34.0 | 37.0 | 46.0 | 59.0 |
| Sex (% female)           | 53.0 | 50.0 | 57.0 | 74.0 |
| Education (years)        | 15.4 (2.5) | 15.3 (2.4) | 15.0 (2.6) | 14.7 (2.4) |
| BMI (kg/m²)              | 24.5 (3.7) | 26.8 (4.5) | 28.8 (5.5) | 33.0 (7.5) |
| Smoking (% current)      | 13.7 | 19.4 | 18.8 | 23.3 |
| Alcohol (% light-moderate) | 45.6 | 43.1 | 40.4 | 35.9 |
| Alcohol (% heavy)        | 12.1 | 12.7 | 12.7 | 9.5  |
| Physical activity        | 388.9 (277.8) | 372.9 (273.6) | 348.1 (274.0) | 278.9 (252.9) |
| Carotenoid index         | 81.3 (45.5) | 69.2 (36.1) | 61.9 (32.0) | 52.3 (26.4) |
| **Endothelial dysfunction** |    |    |    |    |
| ICAM-1                   |      |      |      |      |
| N                        | 597  | 589  | 571  | 582  |
| ICAM-1 (ng/mL)           | 111.3 (10.8) | 134.9 (5.6) | 157.0 (7.2) | 204.3 (33.2) |
| Age (years)              | 40.2 (3.5) | 40.2 (3.6) | 40.0 (3.6) | 40.1 (3.8) |
| Race (% black)           | 29.0 | 36.0 | 50.0 | 62.0 |
| Sex (% female)           | 64.0 | 57.0 | 56.0 | 55.0 |
Table 1 continued

|               | Q1         | Q2         | Q3         | Q4         |
|---------------|------------|------------|------------|------------|
| Education     | 15.8 (2.3) | 15.5 (2.5) | 15.0 (2.5) | 14.2 (2.2) |
| BMI (kg/m²)   | 25.7 (4.7) | 27.3 (5.7) | 29.2 (6.0) | 30.9 (7.3) |
| Smoking       | 7.9        | 11.5       | 18.4       | 38.3       |
| Alcohol (%)   | 48.5       | 42.9       | 36.7       | 36.7       |
| Alcohol (%)   | 12.5       | 9.7        | 11.6       | 13.3       |
| Physical activity | 388.0 (284.7) | 368.0 (270.7) | 341.5 (277.4) | 290.2 (247.5) |
| Carotenoid index | 80.0 (38.6)   | 70.5 (36.6)  | 63.2 (38.3) | 50.6 (27.0) |

E-selectin

|               | Q1         | Q2         | Q3         | Q4         |
|---------------|------------|------------|------------|------------|
| N             | 591        | 580        | 583        | 585        |
| E-selectin (ng/mL) | 18.4 (4.3) | 29.0 (2.5) | 38.0 (2.7) | 51.7 (7.4) |
| Age (years)   | 40.3 (3.6) | 40.1 (3.5) | 40.1 (3.7) | 39.9 (3.8) |
| Race (% black)| 31.0       | 38.0       | 49.0       | 59.0       |
| Sex (% female)| 71.0       | 63.0       | 53.0       | 45.0       |
| Education     | 15.7 (2.4) | 15.2 (2.5) | 15.1 (2.5) | 14.5 (2.3) |
| BMI (kg/m²)   | 26.1 (5.6) | 27.2 (5.4) | 29.2 (6.3) | 30.6 (6.9) |
| Smoking       | 11.0       | 17.1       | 20.5       | 27.2       |
| Alcohol (%)   | 42.7       | 42.0       | 41.8       | 38.5       |
| Alcohol (%)   | 11.4       | 10.4       | 10.6       | 14.8       |
| Physical activity | 357.1 (274.2) | 351.7 (272.0) | 348.5 (285.6) | 332.6 (258.7) |
| Carotenoid index | 78.1 (40.5) | 69.7 (40.1) | 60.5 (31.3) | 56.0 (31.8) |

P-selectin

|               | Q1         | Q2         | Q3         | Q4         |
|---------------|------------|------------|------------|------------|
| N             | 575        | 590        | 592        | 574        |
| P-selectin (ng/mL) | 24.5 (4.0) | 32.4 (1.7) | 38.8 (2.0) | 50.8 (10.7) |
| Age (years)   | 40.3 (3.6) | 39.9 (3.6) | 40.1 (3.8) | 40.2 (3.6) |
| Race (% black)| 41.0       | 44.0       | 48.0       | 43.0       |
| Sex (% female)| 73.0       | 65.0       | 54.0       | 40.0       |
| Education     | 15.6 (2.5) | 15.0 (2.4) | 14.9 (2.4) | 14.0 (2.5) |
| BMI (kg/m²)   | 26.9 (5.7) | 27.9 (6.2) | 29.2 (6.5) | 29.0 (6.5) |
| Smoking       | 11.8       | 17.3       | 18.3       | 28.5       |
| Alcohol (%)   | 40.8       | 41.8       | 39.6       | 43.0       |
| Alcohol (%)   | 11.6       | 10.3       | 12.0       | 13.4       |
| Physical activity | 354.3 (279.1) | 333.6 (262.6) | 356.7 (277.5) | 346.6 (272.6) |
| Carotenoid index | 73.0 (38.6) | 66.7 (40.5) | 62.9 (33.2) | 62.1 (34.9) |

VCAM

|              | Q1         | Q2         | Q3         | Q4         |
|--------------|------------|------------|------------|------------|
| N            | 489        | 497        | 502        | 494        |
| VCAM (ng/mL) | 352.0 (48.1) | 457.0 (25.7) | 554.3 (30.4) | 741.1 (148.1) |
| Age (years)  | 39.8 (3.7) | 40.0 (3.7) | 40.0 (3.6) | 40.7 (3.5) |
| Race (% black)| 67.0       | 49.0       | 39.0       | 22.0       |
| Sex (% female)| 61.0       | 59.0       | 57.0       | 56.0       |
| Education    | 14.7 (2.4) | 15.2 (2.5) | 15.2 (2.5) | 15.5 (2.5) |
| BMI (kg/m²)  | 29.7 (6.1) | 28.9 (6.5) | 28.2 (6.5) | 26.2 (5.5) |
| Smoking      | 24.6       | 20.3       | 16.6       | 13.6       |
| Alcohol (%)  | 39.0       | 40.2       | 39.2       | 46.8       |
| Alcohol (%)  | 13.6       | 11.9       | 11.9       | 9.8        |
| Physical activity | 323.2 (257.7) | 345.7 (286.8) | 350.3 (269.3) | 371.2 (275.3) |
| Carotenoid index | 63.1 (33.5) | 64.4 (32.5) | 67.5 (40.2) | 70.2 (41.6) |

* Alcohol: light-moderate (>0 to ≤7 drinks/week female, >0 to ≤14 drinks/week male)
* Alcohol: heavy (>7 drinks/week female, >14 drinks/week male)
* Physical activity: exercise units
Risk (RR) for the 75 vs 25th % of the alternative risk score Probability was RR = 1.09, 95 % Confidence interval (1.06–1.13), P < 0.0001. Therefore, there was a relative 9 % improvement in prediction probability with the alternative risk score adding markers of endothelial dysfunction to the base risk score. Alternatively, CRP did not improve prediction probability of diabetes (data not reported).

We carried out a number of sensitivity analyses. There was no evidence that the associations differed for any of the measures by race, sex or BMI. In analyses that accounted for the overall individual factors comprising metabolic syndrome, rather than a continuous score, as well as LDL cholesterol, we observed no material differences in the findings except this approach led to less precise estimates and model fits. Further adjustment for year 15 blood pressure medication also did not affect the results. In another approach we further adjusted for year 15 adiponectin, a potential mediator of these markers and T2D, and this did not impact any of the findings. Since dysglycemia contributes to an environment of oxidative stress, inflammation and endothelial dysfunction we excluded all participants with impaired fasting glucose (IFG) (N = 357) at year 15 and this also didn't alter the nature of any of the results, neither did excluding glucose from the continuous metabolic risk score. Furthermore, we examined whether the results were dependent on the presence of subclinical cardiovascular disease (CAC) at year 15; neither adjustment for year 15 CAC nor exclusion of 182 participants with any CAC had any material effect on the results.

**Discussion**

This population based study, comprised of young to early middle aged black and white adults, showed that biomarkers of an etiological network of oxidative stress, inflammatory, and endothelial dysfunction biomarkers predicted T2D. Biomarkers of oxidative stress, F2-isoprostanones and oxidized LDL, were positively associated with incident T2D, however, adjustment for BMI

---

**Table 2** Hazard ratio and 95 % confidence interval of type 2 diabetes according to measures of oxidative stress and inflammation: CARDIA year 15–25 (2000–2001 to 2010–11)

| Oxidative stress | Q1 | Q2 | Q3 | Q4 | P trend |
|------------------|----|----|----|----|---------|
| **F2-isoprostanones** |    |    |    |    |         |
| N cases/N        | 36/591 | 45/576 | 56/579 | 85/593 |         |
| Model 1          | 1.00 | 1.12 (0.72–1.75) | 1.25 (0.81–1.93) | 1.83 (1.18–2.83) | 0.005 |
| Model 2          | 1.00 | 1.09 (0.70–1.70) | 1.28 (0.83–1.98) | 1.61 (1.03–2.52) | 0.11 |
| Model 3          | 1.00 | 1.10 (0.71–1.72) | 1.14 (0.73–1.76) | 1.22 (0.77–1.93) | 0.86 |
| Model 4          | 1.00 | 1.19 (0.76–1.86) | 1.17 (0.75–1.81) | 1.43 (0.90–2.26) | 0.71 |
| **Oxidized LDL** |    |    |    |    |         |
| N cases/N        | 31/580 | 43/588 | 70/598 | 78/573 |         |
| Model 1          | 1.00 | 1.25 (0.79–1.99) | 2.06 (1.34–3.17) | 1.97 (1.27–3.05) | 0.0006 |
| Model 2          | 1.00 | 1.29 (0.81–2.05) | 2.16 (1.41–3.31) | 2.09 (1.37–3.18) | <0.0001 |
| Model 3          | 1.00 | 1.03 (0.65–1.65) | 1.76 (1.14–2.71) | 1.46 (0.94–2.28) | 0.03 |
| Model 4          | 1.00 | 1.06 (0.66–1.70) | 1.62 (1.05–2.51) | 1.31 (0.83–2.04) | 0.14 |

| Inflammation | C-reactive protein |    |    |    |         |
|--------------|-------------------|----|----|----|---------|
| N cases/N    | 18/582 | 44/602 | 51/587 | 109/568 |         |
| Model 1      | 1.00 | 1.88 (1.08–3.28) | 1.97 (1.14–3.39) | 3.98 (2.36–6.71) | <0.0001 |
| Model 2      | 1.00 | 1.83 (1.05–3.18) | 1.67 (0.96–2.90) | 2.95 (1.73–5.04) | <0.0001 |
| Model 3      | 1.00 | 1.63 (0.93–2.84) | 1.42 (0.82–2.48) | 2.06 (1.17–3.61) | 0.09 |
| Model 4      | 1.00 | 1.64 (0.94–2.87) | 1.41 (0.81–2.46) | 2.21 (1.26–3.88) | 0.022 |

**Oxidative stress**

*Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, physical activity, family history, serum carotenoids and tocopherols, Model 2 Model 1 + alternative oxidative stress marker, inflammation (C-reactive protein), endothelial dysfunction (CAMs), Model 3 Model 2 + BMI, Model 4 Model 3 + Continuous Metabolic Syndrome Score*

**Inflammation**

*Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, physical activity, family history, serum carotenoids and tocopherols, Model 2 Model 1 + oxidative stress (oxldl, isoprostanes), endothelial dysfunction (CAMS), Model 3 Model 2 + BMI, Model 4 Model 3 + continuous metabolic syndrome score, P Trend P value for continuous variable*
attenuated the association. We corroborated that inflammation (C-reactive protein) was positively associated with T2D even with full adjustment for related pathways. Lastly, we observed that higher levels of a plasma biomarker of endothelial dysfunction (E-selectin) were strongly associated with T2D even after full adjustment, although another CAM (ICAM-1) was attenuated upon adjustment for metabolic risk factors. An index of these two CAMs revealed an extended dose–response with a greater magnitude of association; whereas the other two CAMs measured (P-selectin and VCAM) were not associated with T2D. Overall, the addition of E-selectin and ICAM-1 improved the prediction of T2D over a common base risk model. There was no evidence any of these

**Table 3** Hazard ratio and 95% confidence interval of type 2 diabetes according to measures of endothelial dysfunction: CARDIA year 15–25 (2000–2001 to 2010–11)

|         | Q1             | Q2             | Q3             | Q4             | P trend |
|---------|----------------|----------------|----------------|----------------|---------|
| **ICAM-1** |                |                |                |                |         |
| N cases/N | 21/597         | 41/589         | 59/571         | 101/582        |         |
| Model 1  | 1.00           | 1.73 (1.02–2.93)| 2.28 (1.37–3.78)| 3.20 (1.94–5.27)| <0.0001 |
| Model 2  | 1.00           | 1.47 (0.87–2.51)| 1.73 (1.03–2.91)| 1.94 (1.14–3.31)| 0.11    |
| Model 3  | 1.00           | 1.37 (0.81–2.34)| 1.56 (0.92–2.62)| 1.72 (1.01–2.94)| 0.07    |
| Model 4  | 1.00           | 1.31 (0.77–2.25)| 1.50 (0.89–2.52)| 1.64 (0.96–2.81)| 0.20    |
| **E-selectin** |                |                |                |                |         |
| N cases/N | 28/591         | 32/580         | 61/583         | 101/585        |         |
| Model 1  | 1.00           | 0.99 (0.59–1.65)| 1.69 (1.07–2.66)| 2.48 (1.60–3.85)| <0.0001 |
| Model 2  | 1.00           | 1.00 (0.59–1.68)| 1.56 (0.97–2.49)| 2.10 (1.31–3.38)| <0.0001 |
| Model 3  | 1.00           | 1.01 (0.60–1.69)| 1.34 (0.84–2.15)| 1.76 (1.09–2.83)| 0.0008  |
| Model 4  | 1.00           | 0.99 (0.59–1.67)| 1.30 (0.81–2.09)| 1.68 (1.04–2.71)| 0.0016  |
| **P-selectin** |                |                |                |                |         |
| N cases/N | 41/575         | 42/590         | 67/592         | 70/574         |         |
| Model 1  | 1.00           | 0.92 (0.59–1.41)| 1.38 (0.93–2.06)| 1.48 (0.98–2.22)| 0.97    |
| Model 2  | 1.00           | 0.76 (0.68–1.54)| 1.02 (0.68–1.54)| 0.93 (0.60–1.43)| 0.58    |
| Model 3  | 1.00           | 0.78 (0.50–1.22)| 0.96 (0.64–1.45)| 0.89 (0.58–1.37)| 0.49    |
| Model 4  | 1.00           | 0.78 (0.50–1.21)| 0.93 (0.62–1.41)| 0.80 (0.52–1.24)| 0.32    |
| **VCAM** |                |                |                |                |         |
| N cases/N | 58/489         | 56/497         | 42/502         | 30/494         |         |
| Model 1  | 1.00           | 1.14 (0.79–1.66)| 0.86 (0.57–1.29)| 0.75 (0.47–1.19)| 0.30    |
| Model 2  | 1.00           | 1.16 (0.80–1.69)| 0.87 (0.58–1.32)| 0.71 (0.43–1.15)| 0.09    |
| Model 3  | 1.00           | 1.09 (0.75–1.59)| 0.89 (0.59–1.34)| 0.78 (0.48–1.29)| 0.28    |
| Model 4  | 1.00           | 1.04 (0.71–1.52)| 0.85 (0.56–1.28)| 0.83 (0.51–1.38)| 0.31    |

Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, physical activity, family history, carotenoids and tocopherols, Model 2 Model 1 + other endothelial dysfunction markers (CAMs), oxidative stress (oxldl, isoprostanes), inflammation (CRP), Model 3 Model 2 + BMI, Model 4 Model 3 + continuous metabolic syndrome score

**Table 4** Hazard ratio and 95% confidence interval of type 2 diabetes according to endothelial dysfunction index (E-selectin + ICAM-1) CARDIA year 15–25 (2000–2001 to 2010–11)

| Rank sum | 2–3 | 4 | 5 | 6 | 7 | 8 | P trend |
|----------|-----|----|----|----|----|----|---------|
| N cases/N | 22/568 | 22/396 | 24/379 | 43/387 | 51/320 | 60/267 |         |
| Model 1  | 1.00 | 1.31 (0.72–2.37) | 1.37 (0.76–2.46) | 2.23 (1.32–3.78) | 2.90 (1.72–4.89) | 3.76 (2.23–6.34) | <0.0001 |
| Model 2  | 1.00 | 1.23 (0.68–2.23) | 1.25 (0.70–2.26) | 2.03 (1.19–3.44) | 2.53 (1.49–4.28) | 3.07 (1.79–5.25) | <0.0001 |
| Model 3  | 1.00 | 1.13 (0.63–2.06) | 1.09 (0.60–1.98) | 1.81 (1.06–3.09) | 2.00 (1.16–3.45) | 2.49 (1.43–4.33) | <0.0001 |
| Model 4  | 1.00 | 1.22 (0.67–2.23) | 1.04 (0.57–1.90) | 1.91 (1.11–3.27) | 1.92 (1.11–3.30) | 2.34 (1.34–4.09) | 0.0002 |

Rank sum combined rank sum of quartiles of E-selectin and ICAM-1(1–4 each, 8 total possible), Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, physical activity, family history, carotenoids and tocopherols, Model 2 Model 1 + oxidative stress (oxidized LDL, isoprostanes) and inflammation (CRP), Model 3 Model 2 + BMI, Model 4 Model 3 + continuous metabolic syndrome score
results were modified by race, sex, BMI, IFG, adiponectin, or sub-clinical CVD (CAC).

The results from this study related to oxidative stress contribute novel data to the literature as there has been little prospective study of the association between plasma markers of oxidative stress and T2D. In a case-cohort analysis from the ARIC study higher levels of oxidized LDL were positively associated with T2D in a simple model, and in the context of high levels of ICAM-1, but with further adjustment for established risk factors there was no association [18]. Similar results were observed in the Framingham Heart Study for urinary isoprostanes [38]. On the other hand higher urinary isoprostane levels in the IRAS study were inversely associated with T2D [9]. Indeed, urine and plasma measures of isoprostanes are not necessarily equivalent measures [39]. Furthermore, oxidized LDL and isoprostanes represent different aspects of oxidative stress where the former likely represents a local measure in the vasculature and the latter a more general marker of a specific oxidation pathway [40]. These differences may explain the subtleties in the association with T2D in this study.

The results from this analysis related to CRP are confirmatory [11], but the context and population we examined the question in is unique with factors that are likely upstream, downstream and co-determinants. Unlike measures of inflammation only a few studies have examined vascular biomarkers of endothelial dysfunction and risk of T2D. The Nurses’ Health Study observed a strong positive association between higher levels of E-selectin and ICAM-1 with T2D and a non-significant association with VCAM [14]. The WHI had similar findings [16]. The MONICA study observed a similar trend with E-selectin but the ICAM-1 association was only apparent in simple models [15]. The ARIC study only observed a positive association between high levels of ICAM-1 and T2D with high levels of oxidized LDL providing evidence for the hypothesis that endothelial dysfunction needs the presence of oxidative stress to alter T2D risk. We observed a higher incidence rate of T2D with higher levels of
ICAM-1 regardless of oxidized LDL level, although the highest rates were in those with the highest levels of oxidized LDL (data not presented).

The results from this analysis are largely consistent with the results from the Nurses’ Health Study and the WHI even with the different design and modeling approach. The population in this analysis was a sample from a community based study, was significantly younger and diverse by race, sex, and socioeconomic position. The results related to the index of levels of E-selectin and ICAM-1 suggest that high levels of both portend a greater risk for T2D than individual consideration of each CAM. Aligned with these results related to vascular biomarkers of endothelial dysfunction and T2D risk are a handful of studies that observed a positive association between other measures of endothelial dysfunction and increased risk of T2D [41–44]. Lastly, despite the evidence of an etiologic role of these markers of oxidative stress, inflammation and endothelial dysfunction in the development of T2D the addition of them to established clinical risk prediction equations did not improve prediction [38, 45, 46]. Highlighting the differences between etiology and prediction. Yet, the endothelial dysfunction biomarkers improved prediction in the current study.

These population studies are evidence in support of vascular dysfunction in the etiology of T2D. But to give this research context it is important to also consider evidence and mechanisms at the cellular level. This literature suggests these factors under study are likely functioning in a cascade or network with pathophysiological consequences [1], but evidence for each has a demonstrated role in the etiology of T2D. Specifically, generalized oxidative stress damages mitochondria and dulls insulin secretion [5]. Oxidized LDL may have an etiologic role by reducing insulin signaling [47], and glucose uptake [48]. In an inflammatory state a cascade of reactions occur that harm vascular reactivity and insulin delivery and lead to insulin resistance [49]. Lastly, clinical and experimental studies suggest that endothelial dysfunction, likely in the capillary and arteriolar endothelium, which are metabolically involved with insulin-sensitive tissues, is the controlling factor for the amount of insulin that effectively reaches the tissues [50]. Thus, there is a strong basic biological precedent for the population level results we and others have observed.

Strengths of this research include the novelty of prospectively examining the association between serum and plasma biomarkers of oxidative stress and endothelial dysfunction with T2D in the context of one another and inflammation. Furthermore, the ability to characterize the metabolic and cardiovascular risk status of the population, and to demonstrate that the observed results were not due to an underlying condition, strengthens the etiological insight this study provides. Additionally, CARDIA has maintained a high participation rate and high quality data collection through rigorous quality-control procedures throughout the study. Thus, the results from this large community-based sample are generalizable to women, men, blacks and whites. Further, the ability to examine this topic in a younger population (age 33–45 years) is a unique contribution to the literature. Limitations include interpretation of the oxidative stress results—the measures of oxidative stress were not correlated with each other, which reflects the complexity of oxidative stress, and emphasizes caution in extrapolating these results to other measures related to oxidative stress. CRP is a non-specific marker of inflammation and other measures such as IL-6, which drive the production of CRP in the liver may be more specific relative to this topic [49]. Endothelial dysfunction was assessed solely by serum/plasma biomarkers and we did not have other measures of vascular physiology. Regardless of measurement, consideration of residual confounding is important in any observational study.

Conclusions
These findings extend the literature from earlier studies on circulating measures of endothelial dysfunction and risk of T2D, and contribute novel data related to oxidative stress and risk of T2D by assessing these factors in the context of one another and other relevant pathways including a marker of inflammation, metabolic syndrome components and BMI. Overall, these results demonstrate that higher circulating levels of oxidative stress, inflammatory and endothelial dysfunction biomarkers clearly precede the development of T2D.

Authors’ contributions
AOC: Conceived topic, designed and carried out analysis, interpreted data, drafted the article and revised for content and approved submitted version (Guarantor). DRU: Contributed to conception of topic and analytic design, interpreted data, contributed to drafting a section of the article, and critically reviewed the article for intellectual content. Approved submitted version. OAS, DCG, APR, MDG: Contributed to interpretation of the data, critically reviewed the article for intellectual content, and approved submitted version. All authors read and approved the final manuscript.

Author details
1 Department of Epidemiology, School of Medicine, University of California-Irvine, Irvine, CA 92697-7550, USA. 2 Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, USA. 3 Department of Epidemiology, Colorado School of Public Health, University of Colorado, Denver, USA. 4 Department of Epidemiology, School of Public Health, University of Washington, Seattle, USA. 5 Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, USA.

Competing interests
The authors declare that they have no competing interests.

Funding
The coronary artery risk development in young adults study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham.
38. Dallmeier D, Larson MG, Wang N, Fontes JD, Benjamin EJ, Fox CS. Addition of inflammatory biomarkers did not improve diabetes prediction in the community: the framingham heart study. J Am Heart Assoc. 2012;1:e000869.

39. Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal. 2010;13:145–56.

40. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol. 2004;142:231–55.

41. Meigs JB, O'Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson P.W. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006;55:530–7.

42. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care. 2005;28:702–7.

43. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999;22:767.

44. Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care. 2008;31:995–1000.

45. Raynor LA, Pankow JS, Duncan BB, Schmidt MI, Hoogeveen RC, Pereira MA, Young JH, Ballantyne CM. Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2013;36:70–6.

46. Chao C, Song Y, Cook N, Tseng CH, Manson JE, Eaton C, Margolis KL, Rodriguez B, Phillips LS, Tinker LF, Liu S. The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med. 2010;170:1557–65.

47. Mazière C, Mollière P, Santus R, Marcheux V, Louandre C, Conte MA, Mazière JC. Inhibition of insulin signaling by oxidized low density lipoprotein. Protective effect of the antioxidant Vitamin E. Atherosclerosis. 2004;175:23–30.

48. Maddux BA, See W, Lawrence JC Jr, Goldfine AL, Goldfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of alpha-lipoic acid. Diabetes. 2001;50:404–10.

49. Gabay C, Kuthner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.

50. Pinkney JH, Strehouwer CD, Copping SW, Yardin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46:s9–13.